PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Sinclair & Co.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Metrics Unveils State-of-Art Cytotoxic Drug Facility - New facility will feature dedicated equipment and change parts with no open processes - MetricsInc.com
Metrics Unveils State-of-Art Cytotoxic Drug Facility

 

NewswireToday - /newswire/ - Greenville, NC, United States, 2008/11/18 - New facility will feature dedicated equipment and change parts with no open processes - MetricsInc.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In early 2009, Metrics Inc. will open a state-of-the-art dedicated potent and cytotoxic drug development facility.

As part of Metrics’ recent $18-million expansion, the new dedicated facility will provide total engineered containment of pharmaceutical processes through customized hard-wall isolation technologies.

Because of these technologies, Metrics’ has eliminated any need for the use of powered air purifying respirators (PAPRs) in its new potent facility. Equipment and change parts are dedicated exclusively to potent and cytotoxic use, and containment is achieved at levels approximately 30 nanograms per cubic meter of room air.

All of which makes Metrics’ dedicated potent and cytotoxic facility unique within its industry. “According to our internal research, Metrics’ new facility has raised the industry bar in providing potent handling capabilities for clients,” said Phil Hodges, president. “Given the enormous growth in demand for potent handling capabilities, I am confident that our facility will attract clients because of the safety, security and reliability Metrics offers for client studies and employees alike.”

Metrics Inc. (metricsinc.com), headquartered in Greenville, N.C., provides quality pharmaceutical formulation development, clinical trial material (Phase I, II and III) and commercial manufacturing, and analytical development/validation services to the pharmaceutical industry.

Thanks to its recent 47,000-square-foot facility addition, Metrics now offers four new analytical laboratories, bringing to seven the total number of analytical laboratories. The labs are fully operational, validated and ready for projects.

Also as part of its recent expansion, Metrics provides stability storage with environmental specialties chambers complete with redundant mechanical systems and strictly limited personnel access. The company brought antibiotic assay and sterility testing online, enhancing its ability to offer full microbiological support of sterile products.

Metrics’ new potent and cytotoxic facility will feature two processing rooms that come complete with independent entry double airlocks, independent decontamination showers and exit airlocks, independent equipment airlocks, and access to an dedicated washroom. It is designed for one-way flow of material, personnel and equipment.

A dedicated air handler will bring in 100-percent outside air with HEPA-in and HEPA-out filtering at the rate of 11,000-cubic-feet per minute and 25 air changes per hour. There are pass throughs for the export of product and waste as well as dedicated equipment storage.

“We’ve increased our capacity to safely work with more potent active pharmaceutical ingredients by reducing exposure to 30 nanograms per cubic meter, making us a leader within our industry,” Hodges said.

After every campaign, Metrics staff will conduct comprehensive health-based cleaning verification of shared surface areas. The isolated equipment that is permanently housed inside the potent facility includes:
• Fluid Energy Jet-O-Mizer micronizer;
• Fitzpatrick Fitz L1A;
• Globe Pharma Mexi-Blend (0.5 to 16 quart);
• Vector TFC Lab micro roller compactor;
• Fluid Air Pharm X High Shear Granulator with 1L, 2L, 4L and 8L bowls;
• Vector FLM1 fluid bed dryer / top-spray granulator;
• Quardro Comil U-5 model;
• Riva 10-station instrumented Picolla tablet press;
• Capsule filling devices;
• Tablet film coater.

Because of its $18-million facility expansion, Metrics is increasing staff, adding at least 50 pharmaceutical scientists and technicians, among them industry veterans with the experience to oversee projects from conception through completion.

Metrics is one of the fastest-growing contract pharmaceutical development laboratories in the United States today.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Sinclair & Co.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Metrics Unveils State-of-Art Cytotoxic Drug Facility

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Karen Stinneford - Sinclair-Co.com 
919-833-9102 kstinneford[.]sinclair-co.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sinclair & Co. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Sinclair & Co. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)